Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
93.3 CHF | -0.20% | +3.05% | +9.93% |
Sales 2024 * | 48.96B 44.23B | Sales 2025 * | 50.79B 45.89B | Capitalization | 210B 190B |
---|---|---|---|---|---|
Net income 2024 * | 10.42B 9.42B | Net income 2025 * | 11.92B 10.77B | EV / Sales 2024 * | 4.55 x |
Net Debt 2024 * | 12.44B 11.24B | Net Debt 2025 * | 11.34B 10.25B | EV / Sales 2025 * | 4.37 x |
P/E ratio 2024 * |
20.2
x | P/E ratio 2025 * |
17.3
x | Employees | 76,057 |
Yield 2024 * |
3.5% | Yield 2025 * |
3.64% | Free-Float | 85.22% |
Latest transcript on Novartis AG
1 day | +0.03% | ||
1 week | +3.05% | ||
Current month | +4.77% | ||
1 month | +7.86% | ||
3 months | +6.07% | ||
6 months | +11.58% | ||
Current year | +9.93% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 48 | 04-12-31 | |
Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
Chairman | 68 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
10.40% | 121 M€ | -.--% | - | |
5.57% | 17 M€ | +7.01% | - | |
4.12% | 88 M€ | +10.37% | - | |
3.79% | 2 M€ | -25.75% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 93.3 | -0.20% | 2 502 334 |
24-05-14 | 93.49 | +0.45% | 2,742,580 |
24-05-13 | 93.07 | +0.81% | 3,892,615 |
24-05-10 | 92.32 | +1.97% | 3,233,804 |
24-05-08 | 90.54 | +0.85% | 2,553,649 |
Delayed Quote Swiss Exchange, May 15, 2024 at 11:30 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.93% | 210B | |
+31.37% | 588B | |
-3.23% | 364B | |
+19.38% | 326B | |
+5.25% | 285B | |
+14.83% | 239B | |
-6.95% | 200B | |
+10.05% | 167B | |
+0.09% | 161B | |
+0.89% | 124B |
- Stock Market
- Equities
- NOVN Stock